Compare PKE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | IRWD |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.4M | 687.4M |
| IPO Year | 1994 | 2009 |
| Metric | PKE | IRWD |
|---|---|---|
| Price | $26.85 | $3.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $42.50 | $6.10 |
| AVG Volume (30 Days) | 293.9K | ★ 2.1M |
| Earning Date | 10-08-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | 93.10 | ★ 1400.00 |
| EPS | 0.37 | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $16.24 | $59.19 |
| Revenue Next Year | $17.78 | $4.80 |
| P/E Ratio | $71.00 | ★ $6.85 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $18.25 | $1.44 |
| 52 Week High | $39.86 | $5.78 |
| Indicator | PKE | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 39.40 |
| Support Level | $25.70 | $3.04 |
| Resistance Level | $29.36 | $3.96 |
| Average True Range (ATR) | 1.17 | 0.18 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 24.33 | 15.14 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.